Business
Payer coverage expansion of KidneyIntelX
Payer coverage expansion of KidneyIntelX.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH, CEO.\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nPayer coverage expansion of KidneyIntelX\n \nLONDON and SALT LAKE CITY - September 22, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, discloses that it has signed a contract with BlueCross and BlueShield of Texas (BCBSTX), the largest statewide health care plan serving 7 million members in all 254 Texas counties, to expand insurance coverage of KidneyIntelX™ in the state of Texas.\n \nIn addition, Renalytix has executed a contract with Parkland Community Health Plan (PCHP), a Dallas based insurance plan with over 300,000 covered lives and service in seven counties, for insurance coverage of KidneyIntelX.\n \nBlueCross and BlueShield Texas works with more than 140,000 physicians and healthcare practitioners, and 520 hospitals. The BlueCross and BlueShield of Texas agreement complements coverage already secured with several other Blues plans including Wellmark Blue Cross Blue Shield in Iowa and South Dakota (estimated 2.1 million covered lives), BlueCross BlueShield of Illinois (estimated 8.1 million covered lives) and CareFirst BlueCross BlueShield (estimated 3.4 million covered lives). The Company believes that achieving payer coverage with these large state-wide plans is a critical component to bringing the benefits of KidneyIntelX prognostic technology to large populations of adults with type 2 diabetes and early-stage kidney disease.\n \n \nFor further information, please contact:\n \n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nAlex Price / Nicholas Moore / Nick Harland / Samira Essebiyea\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8...